We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Molecular Imaging Transforms Prostate Cancer Management

By MedImaging International staff writers
Posted on 02 Apr 2020
Print article
Image: The Siemens Healthineers Biograph Horizon PET/CT (Photo courtesy of Siemens Healthineers)
Image: The Siemens Healthineers Biograph Horizon PET/CT (Photo courtesy of Siemens Healthineers)
Prostate-specific membrane antigen (PSMA) positron emission tomography computed tomography (PET-CT) improves prostate cancer staging accuracy, claims a new study.

Researchers at the University of Melbourne (UNIMELB; Melbourne, Australia), the University of Western Australia (UWA; Crawley, Australia), and other institutions conducted a study involving 300 men at ten sites across Australia diagnosed with prostate cancer and deemed to be at high risk. The men were randomly assigned to receive either conventional CT and bone scans (152 patients) or PSMA-PET/CT (148 patients). The CT produces detailed body images, while the PET scan detects areas where PSMA is present at high levels, indicating the presence of prostate cancer cells.

The results showed that PSMA-PET/CT scans were much more accurate (92%) than conventional CT and bone scans (65%) at detecting cancer spread. Conventional imaging failed to detect cancer spread in 29 patients, giving a false negative result. By comparison, PSMA-PET/CT gave false negative results in just six patients; furthermore, fewer men had false positive results. While both imaging techniques involved radiation exposure, the dose associated with PSMA-PET/CT was less than half (8.4mSv) of conventional imaging (19.2mSv).

In addition, PSMA-PET/CT scans had greater impact on the way the patients' disease was managed, with 28% having their treatment plans changed following scans, compared with 15% following conventional imaging. And when PSMA-PET/CT was introduced at the second round of imaging (after conventional imaging), disease management plans were still changed in 27% of cases, but when conventional imaging was used at the second round, however, just 5% of patients had their treatment plans changed. The study was published on March 20, 2020, in The Lancet.

“Taken together, our findings indicate that PSMA-PET/CT scans offer greater accuracy than conventional imaging and can better inform treatment decisions,” said lead author Professor Michael Hofman, MBBS, of the Peter MacCallum Cancer Centre at UNIMELB. “We recommend that clinical guidelines should be updated to include PSMA PET/CT as part of the diagnostic pathway for men with high risk prostate cancer.”

PET is a nuclear medicine imaging technique that produces a three dimensional (3D) image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide tracer. Tracer concentrations within the body are then reconstructed in 3D by computer analysis. In modern PET-CT scanners, 3D imaging is often accomplished with the aid of a CT X-ray scan performed on the patient during the same session, in the same machine.

Related Links:
University of Melbourne
University of Western Australia


New
Prostate Cancer MRI Analysis Tool
DynaCAD Urology
Multi-Use Ultrasound Table
Clinton
Computed Tomography System
Aquilion ONE / INSIGHT Edition
Diagnostic Ultrasound System
MS1700C

Print article

Channels

MRI

view channel
Image: The AI tool can help interpret and assess how well treatments are working for MS patients (Photo courtesy of Shutterstock)

AI Tool Tracks Effectiveness of Multiple Sclerosis Treatments Using Brain MRI Scans

Multiple sclerosis (MS) is a condition in which the immune system attacks the brain and spinal cord, leading to impairments in movement, sensation, and cognition. Magnetic Resonance Imaging (MRI) markers... Read more

Nuclear Medicine

view channel
Image: In vivo imaging of U-87 MG xenograft model with varying mass doses of 89Zr-labeled KLG-3 or isotype control (Photo courtesy of L Gajecki et al.; doi.org/10.2967/jnumed.124.268762)

Novel Radiolabeled Antibody Improves Diagnosis and Treatment of Solid Tumors

Interleukin-13 receptor α-2 (IL13Rα2) is a cell surface receptor commonly found in solid tumors such as glioblastoma, melanoma, and breast cancer. It is minimally expressed in normal tissues, making it... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.